Vertex Pharmaceuticals slipped 1.41% to close at $475.49, managing to outperform a much gloomier market where the S&P 500 nose-dived 3.46%. Despite the drop, Vertex flexed its resilience, outpacing ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Utility stocks are often considered a safe haven during economic troubles, and Dominion Energy (NYSE: D) stands out as a prime candidate. With a substantial customer base of 3.6 million in Virginia, ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.